# EDGAR Filing Document

**Accession Number:** 0001631487
**File Stem:** 0001213900-25-115743
**Filing Date:** 2025-11
**Character Count:** 10830
**Document Hash:** 58c66ec99438efc979f4740602c3fad5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-115743.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001213900-25-115743

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CollPlant Biotechnologies Ltd
- **CENTRAL INDEX KEY:** 0001631487
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90478
- **FILM NUMBER:** 251532265

**BUSINESS ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER ST., 11TH FLOOR
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 74140
- **BUSINESS PHONE:** 972-73-232-5600

**MAIL ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER ST., 11TH FLOOR
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 74140

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CollPlant Holdings Ltd.
- **DATE OF NAME CHANGE:** 20190620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CollPlant Biotechnologies Ltd.
- **DATE OF NAME CHANGE:** 20190619

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CollPlant Holdings Ltd.
- **DATE OF NAME CHANGE:** 20150122
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sagy Ami
- **CENTRAL INDEX KEY:** 0001740791

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 66 PINKAS STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 62157

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sagi Ami
- **DATE OF NAME CHANGE:** 20180515

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Collplant Biotechnologies Ltd.**

*(Name of Issuer)*

**Ordinary Shares, par value NIS 1.50 per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio)**

*(Title of Class of Securities)*

**19516R107**

*(CUSIP Number)*

**Jonathan M. Nathan, Adv.**<br>Meitar Law Offices<br>16 Abba Hillel Road Street,<br>Ramat Gan L3 5250608<br>972-3-610-3100

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **19516R107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ami Sagy** | Name of reporting person<br>**Ami Sagy** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1637086.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1637086.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1637086.00** | Aggregate amount beneficially owned by each reporting person<br>**1637086.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.9%** | Percent of class represented by amount in Row (11)<br>**12.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Row 13: The percent of class set forth in row 13 is based on 12,716,014 outstanding ordinary shares as of August 19, 2025, as set forth in the Issuer's Post-Effective Amendment No. 1 to Form F-1, filed by the Issuer with the SEC on August 20, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value NIS 1.50 per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio)

**(b) Name of Issuer:**
Collplant Biotechnologies Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
4 Oppenheimer, Weizmann, Science Park, Rehovot, L3, 7670104

**Item 4. Purpose of Transaction**

The Reporting Person is filing this Amendment No. 4 to Schedule 13D ("Amendment No. 4") to report his sale of 140,000 Ordinary Shares during the period from October 16, 2025 through November 19, 2025. Furthermore, since he last filed Amendment No. 3 to Schedule 13D on November 5, 2019, the Reporting Person's beneficial ownership has decreased materially.

The Reporting Person holds the Ordinary Shares reported herein for investment purposes only. The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions.

Except as described above, as of the filing of this Amendment No. 4, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares, or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's memorandum of association or articles of association or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing the ADSs to be delisted from the Nasdaq Capital Market or any other national securities exchange on which they may be listed in the future, or to cease to be authorized to be quoted in any inter-dealer quotation system of a registered national securities association in which they may be quoted in the future; (i) causing the ADSs to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of the Reporting Person to Rows (11) and (13) of the cover page of this Amendment No. 4 are incorporated herein by reference.

The aggregate percentage of Ordinary Shares reported as beneficially owned by the Reporting Person in this Amendment No. 4 was calculated based on 12,716,014 outstanding Ordinary Shares as of August 19, 2025, as set forth in the Issuer's Post-Effective Amendment No. 1 to Form F-1, filed by the Issuer with the SEC on August 20, 2025.

**(b)**
The responses of the Reporting Person to Rows (7) through (10) of the cover page of this Amendment No. 4 are incorporated herein by reference.

**(c)**
From October 16, 2025 through November 19, 2025, the Reporting Person sold the following number of Ordinary Shares, constituting 140,000 Ordinary Shares in total (via sales of ADSs representing Ordinary Shares), in open market sales on the Nasdaq Capital Market at the following prices per share:

Date                            Number of Shares Sold               Average Price Per Share Sold
10/16/2025                  6,505                                           $2.39
10/17/2025                  1,417                                           $2.32
10/20/2025                   9,969                                          $2.41
10/20/2025                   16,162                                        $2.40
10/20/2025                   13,088                                        $2.40
10/20/2025                   6,875                                          $2.42
10/20/2025                   3,906                                          $2.44
10/21/2025                   8,228                                          $2.40
10/21/2025                   7,454                                          $2.40
10/21/2025                   2,900                                          $2.40
10/22/2025                   9,346                                          $2.31
10/23/2025                   1,167                                          $2.30
10/24/2025                   2,691                                          $2.30
10/28/2025                   6,526                                          $2.33
10/29/2025                   10                                               $2.30
11/7/2025                     8,134                                          $2.02
11/7/2025                     8,094                                          $2.08
11/10/2025                   8,521                                          $1.99
11/12/2025                   8,294                                          $1.89
11/19/2025                   6,406                                          $2.06
11/19/2025                   2,329                                          $2.02

Other than as described immediately above, the Reporting Person has not effected any transactions in the Ordinary Shares during the 60 days preceding the date of this Amendment No. 4.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ami Sagy

**Signature:** /s/ Ami Sagy

**Name/Title:** Ami Sagy

**Date:** 11/28/2025